ফুসফুসৰ কেন্সাৰ (নন-স্মল চেল)
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
ক’ত যাব
ভাৰতৰ 1 খন হস্পিতালত এই trial-ৰ বাবে ৰোগী ভৰ্তি কৰা হৈছে।
ৰেজিষ্ট্ৰীৰ সাৰাংশ (কাৰিকৰী)
Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS penetration rates and have shown favorable response rates in brain metastases. Brain radiotherapy/surgery is the standard treatment in brain metastases especially symptomatic metastases, however, the role of local treatment especially in driver mutation-positive non-small cell lung cancer with asymptomatic brain metastases is being questioned given their potential side effects. No randomized trial has shown the superiority of early vs delayed cranial RT in asymptomatic BM of driver mutated NSCLC.
স্পন্সৰ: টাটা মেম'ৰিয়েল হস্পিটেল
ClinicalTrials.gov ত NCT05236946
ৰেজিস্ট্ৰীত শেষ আপডেট 10 ছেপ্টেম্বৰ 2025 · আমাৰ দ্বাৰা 20 অক্টোবৰ 2026 ত পঢ়া হৈছে